NASDAQ:BMRN
BioMarin Pharmaceutical Inc. Stock News
$80.91
-1.26 (-1.53%)
At Close: Apr 26, 2024
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
12:50pm, Thursday, 25'th Apr 2024
BioMarin's (BMRN) earnings beat estimates in the first quarter of 2024, while revenues slightly miss the mark. The company maintains revenue guidance for 2024.
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
07:31pm, Wednesday, 24'th Apr 2024
The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
06:16pm, Wednesday, 24'th Apr 2024
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.60 per share. This compares to earnings of $0.60 per share a year ago.
Is a Surprise Coming for BioMarin (BMRN) This Earnings Season?
12:41pm, Tuesday, 23'rd Apr 2024
BioMarin (BMRN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Gear Up for BioMarin (BMRN) Q1 Earnings: Wall Street Estimates for Key Metrics
10:22am, Monday, 22'nd Apr 2024
Besides Wall Street's top -and-bottom-line estimates for BioMarin (BMRN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the q
Miracle growth: Discover the biotech stock behind decades of jaw-dropping returns
07:11am, Friday, 15'th Mar 2024
Although many popular biotech stocks peaked in 2020 and early 2021 and then started to decline, early 2024 has seen signs of recovery and a return of investors' trust. Nonetheless, this biotech stock
BioMarin Scheduled to Participate in March Investor Conferences
09:00am, Friday, 01'st Mar 2024
- Cowen 44th Annual Healthcare Conference on March 5 - Leerink Partners Global Biopharma Conference on March 11 - Jefferies Biotech on the Bay Summit on March 12 -�
BioMarin Pharma gets DOJ subpoena on certain drug testing programs
02:14pm, Monday, 26'th Feb 2024
BioMarin Pharmaceutical has received a subpoena from the U.S. Department of Justice seeking information about the company's sponsored testing programs related to two treatments, it said in a filing on
BioMarin Pharmaceutical, Inc. (BMRN) Q4 2023 Earnings Call Transcript
09:08pm, Thursday, 22'nd Feb 2024
BioMarin Pharmaceutical, Inc. (BMRN) Q4 2023 Earnings Call Transcript
Here's What Key Metrics Tell Us About BioMarin (BMRN) Q4 Earnings
07:01pm, Thursday, 22'nd Feb 2024
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Str
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates
06:16pm, Thursday, 22'nd Feb 2024
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.36 per share a year ago.
5 Stocks Likely to Gain on Q4 Earnings Today After Market Close
08:11am, Thursday, 22'nd Feb 2024
We have narrowed our search to five large-cap stocks that are poised to beat on earnings today after market closes. These are: BKNG, AMH, FND, BMRN, PBA.
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More
10:16am, Wednesday, 21'st Feb 2024
Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?
11:06am, Thursday, 15'th Feb 2024
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
06:46am, Thursday, 15'th Feb 2024
Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.